CTIS2022-502978-17-00进行中（未招募）1 期
Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, with or Without Platinum-Based Chemotherapy, in Patients with Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer - GO42501
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only) NSCLC of squamous or non-squamous histology, Eligible for R0 resection with curative intent at the time of screening, as confirmed by the operating attending surgeon and involved medical oncologist prior to study enrollment, Adequate pulmonary function to be eligible for surgical resection, Measurable disease, as assessed by the investigator per RECIST v1.1, Availability of a representative tumor specimen that is suitable for determination of PD-L1 status via central testing, Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
排除标准
- •NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or NSCLC not otherwise specified, Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC, Any prior therapy for lung cancer, Active or history of autoimmune disease or immune deficiency, History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan, NSCLC with an activating EGFR mutation or ALK fusion oncogene
研究者
相似试验
进行中（未招募）
不适用
Open-label, Multicenter, Phase II Study Assessing the Safety of Lucentis (ranibizumab) Administered in Conjunction with Photodynamic Therapy with Visudyne in Patients with Occult or Predominantly Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular DegeneratioMale and female patients > 50 years of age with subfoveal choroidal neovascularization (CNV) secondary to AMD.MedDRA version: 7.0Level: LLTClassification code 10060837EUCTR2004-001453-28-ATovartis Pharma AG30
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 18.1 Level: HLT Classification code 10024579 Term: Lysosomal storage disorders System Organ Class: 100000004850EUCTR2014-000533-22-GBAlexion Pharmaceuticals Inc10
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 17.0Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2014-000533-22-ITSynageva BioPharma Corp.10
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).MedDRA version: 19.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850ysosomal Acid Lipase Deficiency (LALD)EUCTR2014-000533-22-FIAlexion Pharmaceuticals Inc10
招募中
1 期
Phase 2 Study of ZN-c3 in High-Grade Serous Ovarian CancerHigh-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal CancerMedDRA version: 20.0Level: LLTClassification code: 10033130Term: Ovarian cancer NOS Class: 10029104MedDRA version: 21.0Level: LLTClassification code: 10016183Term: Fallopian tube cancer NOS Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10052171Term: Peritoneal carcinoma Class: 10029104CTIS2022-502983-19-00K-Group Beta Inc.474